Trial
NCT05276830
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
BioXcel Therapeutics Inc
Collaborators
Cognitive Research Corporation
Condition
Agitation
Intervention
BXCL501
Why stopped
Study was terminated for business reasons; not due to safety or efficacy concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-03